Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 1

Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2

Authors Allen J Taylor, Daming Zhu, Lance E Sullenberger, Hyun J Lee, Jeannie K Lee, Karen A Grace

Published Date May 2007 Volume 2007:3(1) Pages 159—164

DOI http://dx.doi.org/

Published 18 May 2007

Allen J Taylor, Daming Zhu, Lance E Sullenberger, Hyun J Lee, Jeannie K Lee, Karen A Grace

Cardiology Service, Walter Reed Army Medical Center, Washington, DC, USA

Background: We previously reported in a placebo-controlled study that extended-release niacin slowed the progression of carotid atherosclerosis when added to statin monotherapy. This analysis examines the relationship between glycemic status and the effects of niacin on common carotid intima-media thickness (CIMT) and HDL cholesterol.

Methods: Post-hoc, subgroup analysis of ARBITER 2, a randomized, placebo-controlled trial of once-daily extended-release niacin (1000 mg) added to background statin therapy in 167 patients (mean age 67 years) with known coronary heart disease. The primary analysis was a comparison of the primary endpoint, the change in CIMT, between participants with either normal glycemic status, diabetes mellitus (DM) or the metabolic syndrome (MS).

Results: Baseline cardiovascular risk variables were significantly worse in those with abnormal glycemic status, particularly among subjects with MS. Niacin increased HDL-C to a similar degree (~20%) across normals, DM and MS. Placebo-treated patients had the greatest CIMT progression, regardless of glycemic status. The lowest progression rate was observed in niacin treated patients with normal glycemic status. Among all niacin treated subjects, there was a significant linear relationship between change in CIMT and change in HDL-C (r = –0.16; p = 0.05), which was of similar magnitude in subgroups with normal glycemic status (r = –0.23; p = 0.08) and DM (r = –0.22; p = 0.17). In those with MS, there was no relationship between changes in HDL and CIMT, (r = 0.11; p = 0.44), whereas blood glucose was positive correlated to change in CIMT (r = 0.30; p = 0.04). In multivariable linear models controlling for MS characteristics and blood glucose changes, only the change in HDL independently predicted change in CIMT.

Conclusions: During niacin treatment, increases in HDL-C are related to changes in CIMT in the setting of both normal glycemic status and diabetes mellitus.

Keywords: atherosclerosis, risk factors, lipids, diabetes mellitus

Download Article [PDF] 

Readers of this article also read:

Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations

Fukuda M, Shibata S, Shibata N, Hagihara K, Yaguchi H, Osada H, Takahashi N, Kubo E, Sasaki H

Clinical Ophthalmology 2013, 7:515-520

Published Date: 12 March 2013

The relationship between alexithymia, shame, trauma, and body image disorders: investigation over a large clinical sample

Franzoni E, Gualandi S, Caretti V, Schimmenti A, Di Pietro E, Pellegrini G, Craparo G, Franchi A, Verrotti A, Pellicciari A

Neuropsychiatric Disease and Treatment 2013, 9:185-193

Published Date: 18 February 2013

Sertraline-induced pseudocholinesterase enzyme deficiency

Beyazit Zencirci

International Journal of General Medicine 2010, 3:375-378

Published Date: 16 November 2010

Distribution of bacterial keratitis and emerging resistance to antibiotics in China from 2001 to 2004

Chen Zhang, Yanchuang Liang, Shijing Deng, Zhiqun Wang, Ran Li, Xuguang Sun

Clinical Ophthalmology 2008, 2:575-579

Published Date: 5 October 2008

Detection of metabolic syndrome features among childhood cancer survivors: A target to prevent disease

Adriana Aparecida Siviero-Miachon, Angela Maria Spinola-Castro, Gil Guerra-Junior

Vascular Health and Risk Management 2008, 4:825-836

Published Date: 5 September 2008

Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes

Marc K Israel, Eva Istvan, Michelle A Baron

Vascular Health and Risk Management 2008, 4:1167-1178

Published Date: 2 September 2008

Clinical deterioration after sildenafil cessation in patients with pulmonary hypertension

Anne M Keogh, Andrew Jabbour, Christopher S Hayward, Peter S Macdonald

Vascular Health and Risk Management 2008, 4:1111-1113

Published Date: 20 June 2008

Effect of short-term lycopene supplementation and postprandial dyslipidemia on plasma antioxidants and biomarkers of endothelial health in young, healthy individuals

Steven G Denniss, Thomas D Haffner, Jeffrey T Kroetsch, Sara R Davidson, James WE Rush, Richard L Hughson

Vascular Health and Risk Management 2008, 4:213-222

Published Date: 6 March 2008

Multivariate risk assessment and risk score cards in hypertension

Giuliano Tocci, Valentina Valenti, Sebastiamo Sciarretta, Massimo Volpe

Vascular Health and Risk Management 2007, 3:313-320

Published Date: 15 August 2007